Indeed, pancreatic tumor cells and tissues display different expression profiles of FGFRs (FGFR1-4) [7], and opposite expression trends of FGFR1 and FGFR2 have been recently described in PDAC-derived cell lines [9,10], which lead to the enhancement of alternative signaling pathways and the consequent acquisition of distinct tumor hallmarks [9,10]. The gene discussed is FGFR2; the disease is neoplasm.